Prognostic index for relapsed acute leukemia after allogeneic stem cell transplant

被引：9

作者：

Matsumoto, Kenji ^{[1
]}

Yamamoto, Wataru ^{[1
]}

Ogusa, Eriko ^{[1
]}

Ishigatsubo, Yoshiaki ^{[2
]}

Kanamori, Heiwa ^{[1
]}

机构：

[1] Kanagawa Canc Ctr, Dept Hematol, Yokohama, Kanagawa 2410815, Japan

[2] Yokohama City Univ, Grad Sch Med, Dept Internal Med & Clin Immunol, Yokohama, Kanagawa 232, Japan

来源：

LEUKEMIA & LYMPHOMA | 2014年 / 55卷 / 12期

关键词：

Post-transplant relapse; acute leukemia; prognostic index; ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; BONE-MARROW-TRANSPLANTATION; DONOR LEUKOCYTE INFUSIONS; WORKING PARTY; RISK-FACTORS; ADULTS; AML; MANAGEMENT; OPTIONS;

D O I：

10.3109/10428194.2014.896004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We retrospectively studied patients who relapsed after allogeneic stem cell transplantation (SCT) to identify factors influencing outcomes. Of the 296 patients (196 with AML and 100 with ALL), 102 (34%) experienced relapse at a median of 222 days (range: 30-2,748) after SCT. Multivariable analysis showed that high disease risk (hazard risk [HR]: 1.95; 95% confidence interval [CI]: 1.17-3.24; p = 0.010), unrelated donor (HR: 1.76; 95% CI: 1.10-2.80; p = 0.018), and interval of < 180 days from SCT to relapse (HR: 2.10; 95% CI: 1.26-3.51; p = 0.004) were independent factors of 2-year post-relapse survival (PRS). These factors were used as a prognostic index for PRS. The 2-year PRS in patients of score 0, score 1, score 2, and score 3 was 38%, 19%, 3%, and 0%, respectively (p < 0.001). Our new prognostic index may be helpful for selecting the treatment for relapsed patients after SCT.

引用

页码：2808 / 2812

页数：5

共 20 条

[1] Treatment of relapsed acute leukemia after allogeneic transplantation: A single center experience [J].

Arellano, Martha L. ;

Langston, Amelia ;

Winton, Elliott ;

Flowers, Christopher R. ;

Waller, Edinind K. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (01) :116-123

[2]

Cardoso AA, 1996, BLOOD, V88, P41

[3] Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse [J].

Choi, SJ ;

Lee, JH ;

Kim, S ;

Seol, M ;

Lee, YS ;

Lee, JS ;

Kim, WK ;

Chi, HS ;

Lee, KH .

LEUKEMIA, 2004, 18 (11) :1789-1797

[4] Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation [J].

Collins, RH ;

Shpilberg, O ;

Drobyski, WR ;

Porter, DL ;

Giralt, S ;

Champlin, R ;

Goodman, SA ;

Wolff, SN ;

Hu, W ;

Verfaillie, C ;

List, A ;

Dalton, W ;

Ognoskie, N ;

Chetrit, A ;

Antin, JH ;

Nemunaitis, J .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) :433-444

[5]

Ferrara F, 2004, HAEMATOLOGICA, V89, P998

[6] ADHESION MOLECULE-MEDIATED SIGNALS REGULATE MAJOR HISTOCOMPATIBILITY COMPLEX-UNRESTRICTED AND CD3/T-CELL RECEPTOR-TRIGGERED CYTOTOXICITY [J].

GALANDRINI, R ;

ALBI, N ;

ZARCONE, D ;

GROSSI, CE ;

VELARDI, A .

EUROPEAN JOURNAL OF IMMUNOLOGY, 1992, 22 (08) :2047-2053

[7] Immune escape mechanisms of childhood ALL and a potential countering role for DC-like leukemia cells [J].

Han, P ;

Story, C ;

McDonald, T ;

Mrozik, K ;

Snell, L .

CYTOTHERAPY, 2002, 4 (02) :165-175

[8] Investigation of the freely available easy-to-use software 'EZR' for medical statistics [J].

Kanda, Y. .

BONE MARROW TRANSPLANTATION, 2013, 48 (03) :452-458

[9] GRAFT-VERSUS-LEUKEMIA EFFECT OF DONOR LYMPHOCYTE TRANSFUSIONS IN MARROW GRAFTED PATIENTS [J].

KOLB, HJ ;

SCHATTENBERG, A ;

GOLDMAN, JM ;

HERTENSTEIN, B ;

JACOBSEN, N ;

ARCESE, W ;

LJUNGMAN, P ;

FERRANT, A ;

VERDONCK, L ;

NIEDERWIESER, D ;

VANRHEE, F ;

MITTERMUELLER, J ;

DEWITTE, T ;

HOLLER, E ;

ANSARI, H .

BLOOD, 1995, 86 (05) :2041-2050

[10] Approaches to relapse after allogeneic stem cell transplantation [J].

Kroeger, Nicolaus .

CURRENT OPINION IN ONCOLOGY, 2011, 23 (02) :203-208

← 1 2 →